
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is viewed favorably because its core immunology engine continues to compound, with 3Q26 sales up 10% year over year and Skyrizi and Rinvoq growing 23% and 24%, respectively, while management raised FY 2026 revenue guidance to about $67.8 billion and EPS to $13.95-$13.99. Its outlook is further strengthened by a clean patent runway to 2035+, strong cash generation, and durable franchises that appear to be taking roughly half of new patient starts in key categories, supporting margin leverage as scale builds. The portfolio is also becoming more diversified through the 2020 Allergan deal and the 2024 Cerevel and ImmunoGen acquisitions, while 2026 Apogee adds immunology depth and pipeline optionality.
Bears say
AbbVie is challenged by a deteriorating base business as operating margins come under pressure, EPS growth slows, and valuation could compress from the mid-teens multiple if growth weakens faster than expected. Its outlook is burdened by increasing competition in immunology that could erode Skyrizi and Rinvoq, along with patent challenges, negative pipeline data, and approval delays that threaten key growth drivers across immunology, oncology, and neuroscience. The company also faces material sustainability and execution risks, including government pricing pressure, supply-chain concentration, product-liability exposure, and $3.7 billion in upfront acquisition charges in nine months of 2025, while its Aesthetics business was ~8% of sales in FY 2025 and remains vulnerable to discretionary spending.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About AbbVie (ABBV) Forecast
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares